Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394120 | 1.00 | CRBN (0.46) | CRBNDDB1BRD4CREBBPALDH1A1 | |
| SCHEMBL4400886 | 0.85 | CRBN (0.56) | CRBNDDB1ALDH1A1 | |
| SCHEMBL4400882 | 0.85 | CRBN (0.56) | CRBNDDB1ALDH1A1 | |
| SCHEMBL4388041 | 0.84 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL4399379 | 0.84 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL4388040 | 0.84 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL7268793 | 0.83 | CRBN (0.53) | CRBNDDB1TDP1 | |
| SCHEMBL7268786 | 0.83 | CRBN (0.53) | CRBNDDB1TDP1 | |
| SCHEMBL4388045 | 0.81 | CRBN (0.54) | CRBNDDB1BRD4 | |
| SCHEMBL4388048 | 0.81 | CRBN (0.54) | CRBNDDB1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252144-B1 | SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS | GRUENENTHAL GMBH (DE) | 2009-12-09 | — | — | EP | claimed |
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH (DE) | 2004-03-11 | — | — | US | claimed |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH | 2003-04-03 | — | — | US | claimed |
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885BRD4 1029/4885 |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885BRD4 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.